Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Evaxion Biotech ( (EVAX) ) has issued an update.
Evaxion Biotech announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, effective January 13, 2025. This adjustment, equating to a one-for-five reverse ADS split, is intended to enhance liquidity. The change may increase the ADS trading price, though no guarantees are provided regarding pricing or liquidity impacts.
More about Evaxion Biotech
Evaxion Biotech A/S is a TechBio company leveraging its AI-Immunology platform to develop innovative vaccines and immunotherapies. The company focuses on creating treatments for cancer, bacterial diseases, and viral infections through its clinical-stage oncology and preclinical infectious disease pipelines.
YTD Price Performance: -84.54%
Average Trading Volume: 305,241
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.74M
For an in-depth examination of EVAX stock, go to TipRanks’ Stock Analysis page.
